ArticleJAMA neurology2026

Ten Years of Ocrelizumab in Relapsing Multiple Sclerosis: The OPERA I and II Randomized Clinical Trials.

Stephen L Hauser et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.